StockData
Anavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL) stock

AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 28, 2026Score 6/30
$0.74−0.08 (-9.49%)

Close on Nov 17, 2026Market cap $68.60MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$68.60M
P/E ratio
–
Price to sales
–
Price to book
0.61
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$13.02M
EPS, diluted
-$0.15
Book value per share
$0.00
Diluted shares
92.90B

Trading

Next earnings
Nov 24, 2026 (estimated, before the open)
Previous close
$0.82
Open
$0.83
Day's range
$0.71 – $0.84
Volume
2,272,004
Average volume (20 days)
1,181,518
Index membership
Russell 2000, Russell 3000 (since Nov 2019)
52-week range
$0.71 – $5.36
RSI (14 days)
20.3
Volatility (1 year)
83.1%
Relative volume
2.15×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2010, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodAVXLS&P 500DifferenceAVXL per yearS&P 500 per year
1 month-43.5%-4.0%−39.5 pts
3 months-76.9%-5.0%−72.0 pts
Year to date-79.2%+8.2%−87.5 pts
1 year-79.3%+11.2%−90.5 pts
3 years-88.2%+68.5%−156.7 pts-50.9%+19.0%
5 years-96.5%+67.3%−163.7 pts-48.8%+10.8%
10 years-76.9%+291.6%−368.5 pts-13.6%+14.6%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Operating income

-$17.37M

Net income

-$13.02M

EPS, diluted

-$0.15

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Anavex Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Anavex Life Sciences

Biological Products, (No Diagnostic Substances)

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. The company applies precision medicine and analyzes genomic data from clinical trials to identify biomarkers that guide treatment assessment. Its core research pipeline focuses on compounds that target sigma-1 receptor activation to restore cellular homeostasis. Key product candidates include ANAVEX 2-73, also known as blarcamesine, which is evaluated in oral capsule and liquid formulations, and ANAVEX 3-71. These therapies target conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome.

Company profile, executives and history

Anavex Life Sciences stock: common questions

What is Anavex Life Sciences's stock price?

AVXL closed at $0.74 on Nov 17, 2026, down 9.49% on the day. Over the past 52 weeks it traded between $0.71 and $5.36.

What is Anavex Life Sciences's market cap?

Anavex Life Sciences was worth $68.60M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is AVXL's P/E ratio?

Anavex Life Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.15), so it has no meaningful P/E ratio.

Does Anavex Life Sciences pay a dividend?

No. Anavex Life Sciences has not paid a cash dividend over the last twelve months.

When does Anavex Life Sciences report earnings next?

Anavex Life Sciences is expected to report Q4 FY2026 results on Nov 24, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has AVXL stock performed over the past year?

Including dividends, AVXL returned -79.3% over the past year, against +11.2% for the S&P 500.

How many AVXL shares are sold short?

12M shares were sold short at the latest FINRA report, 13.29% of the float, or 10.1 days of average trading volume.

Who are Anavex Life Sciences's competitors?

Companies most similar to Anavex Life Sciences by business, industry and size include NMRA, ALEC, CGTX, TSHA, PASG.

See a number that looks wrong?